Non-hodgkin lymphoma therapeutics market size to increase by USD 5,427.51 million between 2022 and 2027; Growing awareness about cancer as a key trend - Technavio

NEW YORK, March 24, 2023 /PRNewswire/ -- The non-hodgkin lymphoma therapeutics market size is forecast to grow by USD 5,427.51 million between 2022 and 2027, and the growth momentum will be accelerating at a CAGR of 8.14% during the forecast period. Growing awareness about cancer is identified as the key trend in the market. Various campaigns have been conducted at international and national levels to raise awareness of cancer and support early detection of the disease. Moreover, organizations such as the American Social Health Association (ASHA) and the National Cervical Cancer Coalition (NCCC) are implementing initiatives to raise awareness about cervical cancer prevention and control. Similarly, CDC provides guidelines and conducts awareness programs to screen and vaccinate underserved cervical cancer patients. Collectively, these initiatives are expected to increase awareness about cancer and the available treatments, including various targeted and immunotherapies treating non-hodgkin lymphoma during the forecast period. For more insights on the historic data (2017 to 2021) and forecast market size (2023 to 2027) – Request a report sample

Company Profiles

The non-hodgkin lymphoma therapeutics market report includes information on the key products and recent developments of leading vendors, including:

• AstraZeneca Plc - The company offers non-hodgkin lymphoma therapeutics such as T-cell engagers which are bispecific molecules that are engineered to redirect the immune systems to recognize and kill cancer cells.
• BeiGene Ltd.- The company offers non-hodgkin lymphoma therapeutics such as BRUKINSA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
• Biogen Inc. - The company offers non-hodgkin lymphoma therapeutics targeting CD20 and CD3 in development for B-cell non-hodgkin lymphoma and other blood cancers.
• Bristol Myers Squibb Co. - The company offers non-hodgkin lymphoma therapeutics such as REVLIMID in combination with rituximab (anti-CD20 antibody) for the treatment of adult patients with previously treated follicular lymphoma.

Market Dynamics

The growth of the market is driven by recent approvals and a strong pipeline. Another factor driving the growth of the market is also the growing geriatric population. In addition, special drug designations will also increase market growth. However, limited access to treatment will hinder the growth of the market.

Competitive Analysis

The report includes competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and market performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc. Request a Sample

Market Segmentation

• By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.
• By therapy, the market is segmented into immunotherapy, targeted therapy, and chemotherapy.
• By geography, the market is segmented into North America, Europe, Asia, and Rest of World (ROW).

Why Buy

• Add credibility to strategy
• Analyzes competitor's offerings
• Get a holistic view of the market

Grow your profit margin with Technavio – Buy the Report!

Related Reports:

• The diffuse large B-cell lymphoma (DLBCL) therapeutics market size growth is expected to progress at a CAGR of 7.69% and is estimated at USD 2,061.88 million from 2022 to 2027. The increasing approval of therapeutics for patients with relapsed or refractory DLBCL is notably driving the market growth, although factors such as the high cost of DLBCL treatment may impede the market growth.
• The T-cell lymphoma market is estimated to grow at a CAGR of 8.21% between 2021 and 2026. The size of the market is forecast to increase by USD 768.07 million. The growing geriatric population is notably driving the T-cell lymphoma market growth, although factors such as stringent regulations may impede the market growth.

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

What are the key data covered in this non-hodgkin lymphoma therapeutics market report

• CAGR of the market during the forecast period.
• Detailed information on factors that will drive the growth of the market between 2022 and 2026
• Precise estimation of the size of the non-hodgkin lymphoma therapeutics market and its contribution to the parent market.
• Accurate predictions about upcoming trends and changes in consumer behavior.
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW).
• A thorough analysis of the market's competitive landscape and detailed information about vendors.
• Comprehensive analysis of factors that will challenge the growth of non-hodgkin lymphoma therapeutics market vendors.

Browse through Technavio's Health Care Market Reports

Table of contents:

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Therapy
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global non-hodgkin lymphoma therapeutics market 2017 - 2021 
• Exhibit 18: Historic Market Size – Data Table on Global non-hodgkin lymphoma therapeutics market 2017 - 2021 ($ million)

• 4.2 Therapy Segment Analysis 2017 - 2021 
• Exhibit 19: Historic Market Size – Therapy Segment 2017 - 2021 ($ million)

• 4.3 Distribution channel Segment Analysis 2017 - 2021 
• Exhibit 20: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Distribution Channel

• 6.1 Market segments
• Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)

• 6.2 Comparison by Distribution Channel 
• Exhibit 32: Chart on Comparison by Distribution Channel
• Exhibit 33: Data Table on Comparison by Distribution Channel

• 6.3 Hospital pharmacy - Market size and forecast 2022-2027 
• Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)

• 6.4 Retail pharmacy - Market size and forecast 2022-2027 
• Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)

• 6.5 Online pharmacy - Market size and forecast 2022-2027 
• Exhibit 42: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)

• 6.6 Others - Market size and forecast 2022-2027 
• Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)

• 6.7 Market opportunity by Distribution Channel 
• Exhibit 50: Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by Therapy

• 7.1 Market segments
• Exhibit 51: Chart on Therapy - Market share 2022-2027 (%)
• Exhibit 52: Data Table on Therapy - Market share 2022-2027 (%)

• 7.2 Comparison by Therapy 
• Exhibit 53: Chart on Comparison by Therapy
• Exhibit 54: Data Table on Comparison by Therapy

• 7.3 Immunotherapy - Market size and forecast 2022-2027 
• Exhibit 55: Chart on Immunotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 56: Data Table on Immunotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Chart on Immunotherapy - Year-over-year growth 2022-2027 (%)
• Exhibit 58: Data Table on Immunotherapy - Year-over-year growth 2022-2027 (%)

• 7.4 Targeted therapy - Market size and forecast 2022-2027 
• Exhibit 59: Chart on Targeted therapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 60: Data Table on Targeted therapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Chart on Targeted therapy - Year-over-year growth 2022-2027 (%)
• Exhibit 62: Data Table on Targeted therapy - Year-over-year growth 2022-2027 (%)

• 7.5 Chemotherapy - Market size and forecast 2022-2027 
• Exhibit 63: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 64: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 65: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
• Exhibit 66: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)

• 7.6 Market opportunity by Therapy 
• Exhibit 67: Market opportunity by Therapy ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 69: Chart on Market share by geography 2022-2027 (%)
• Exhibit 70: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 71: Chart on Geographic comparison
• Exhibit 72: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027 
• Exhibit 73: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 75: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027 
• Exhibit 77: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 79: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027 
• Exhibit 81: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 85: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027 
• Exhibit 89: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 UK - Market size and forecast 2022-2027 
• Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.9 Germany - Market size and forecast 2022-2027 
• Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.10 China - Market size and forecast 2022-2027 
• Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.11 Canada - Market size and forecast 2022-2027 
• Exhibit 105: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 106: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 107: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 108: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 109: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 110: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape
• Exhibit 111: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption
• Exhibit 112: Overview on factors of disruption

• 11.4 Industry risks
• Exhibit 113: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 114: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 115: Matrix on vendor position and classification

• 12.3 AstraZeneca Plc
• Exhibit 116: AstraZeneca Plc - Overview
• Exhibit 117: AstraZeneca Plc - Product / Service
• Exhibit 118: AstraZeneca Plc - Key news
• Exhibit 119: AstraZeneca Plc - Key offerings

• 12.4 BeiGene Ltd.
• Exhibit 120: BeiGene Ltd. - Overview
• Exhibit 121: BeiGene Ltd. - Business segments
• Exhibit 122: BeiGene Ltd. - Key offerings
• Exhibit 123: BeiGene Ltd. - Segment focus

• 12.5 Biogen Inc.
• Exhibit 124: Biogen Inc. - Overview
• Exhibit 125: Biogen Inc. - Product / Service
• Exhibit 126: Biogen Inc. - Key offerings

• 12.6 Bristol Myers Squibb Co. 
• Exhibit 127: Bristol Myers Squibb Co. - Overview
• Exhibit 128: Bristol Myers Squibb Co. - Product / Service
• Exhibit 129: Bristol Myers Squibb Co. - Key news
• Exhibit 130: Bristol Myers Squibb Co. - Key offerings

• 12.7 Eisai Co. Ltd.
• Exhibit 131: Eisai Co. Ltd. - Overview
• Exhibit 132: Eisai Co. Ltd. - Business segments
• Exhibit 133: Eisai Co. Ltd. - Key offerings
• Exhibit 134: Eisai Co. Ltd. - Segment focus

• 12.8 F. Hoffmann La Roche Ltd. 
• Exhibit 135: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 136: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 137: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 138: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 139: F. Hoffmann La Roche Ltd. - Segment focus

• 12.9 Gilead Sciences Inc.
• Exhibit 140: Gilead Sciences Inc. - Overview
• Exhibit 141: Gilead Sciences Inc. - Product / Service
• Exhibit 142: Gilead Sciences Inc. - Key news
• Exhibit 143: Gilead Sciences Inc. - Key offerings

• 12.10 GlaxoSmithKline Plc
• Exhibit 144: GlaxoSmithKline Plc - Overview
• Exhibit 145: GlaxoSmithKline Plc - Business segments
• Exhibit 146: GlaxoSmithKline Plc - Key offerings
• Exhibit 147: GlaxoSmithKline Plc - Segment focus

• 12.11 Johnson and Johnson Services Inc. 
• Exhibit 148: Johnson and Johnson Services Inc. - Overview
• Exhibit 149: Johnson and Johnson Services Inc. - Business segments
• Exhibit 150: Johnson and Johnson Services Inc. - Key news
• Exhibit 151: Johnson and Johnson Services Inc. - Key offerings
• Exhibit 152: Johnson and Johnson Services Inc. - Segment focus

• 12.12 Merck KGaA
• Exhibit 153: Merck KGaA - Overview
• Exhibit 154: Merck KGaA - Business segments
• Exhibit 155: Merck KGaA - Key news
• Exhibit 156: Merck KGaA - Key offerings
• Exhibit 157: Merck KGaA - Segment focus

• 12.13 Novartis AG
• Exhibit 158: Novartis AG - Overview
• Exhibit 159: Novartis AG - Business segments
• Exhibit 160: Novartis AG - Key offerings
• Exhibit 161: Novartis AG - Segment focus

• 12.14 Pfizer Inc.
• Exhibit 162: Pfizer Inc. - Overview
• Exhibit 163: Pfizer Inc. - Product / Service
• Exhibit 164: Pfizer Inc. - Key news
• Exhibit 165: Pfizer Inc. - Key offerings

• 12.15 Seagen Inc.
• Exhibit 166: Seagen Inc. - Overview
• Exhibit 167: Seagen Inc. - Product / Service
• Exhibit 168: Seagen Inc. - Key offerings

• 12.16 Spectrum Pharmaceuticals Inc. 
• Exhibit 169: Spectrum Pharmaceuticals Inc. - Overview
• Exhibit 170: Spectrum Pharmaceuticals Inc. - Product / Service
• Exhibit 171: Spectrum Pharmaceuticals Inc. - Key offerings

• 12.17 Teva Pharmaceutical Industries Ltd. 
• Exhibit 172: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 173: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 174: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 175: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 176: Teva Pharmaceutical Industries Ltd. - Segment focus

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 177: Inclusions checklist
• Exhibit 178: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 179: Currency conversion rates for US$

• 13.4 Research methodology
• Exhibit 180: Research methodology
• Exhibit 181: Validation techniques employed for market sizing
• Exhibit 182: Information sources

• 13.5 List of abbreviations 
• Exhibit 183: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio